AI-Optimized CLD

From Screening to Design: Can Production Cell Lines Become Programmable Platforms?

David Alvaro, Ph.D.

Pharma's Almanac

BsAbs

Why Bispecific Antibody Architecture Is a CMC Decision

David Alvaro, Ph.D.

Pharma's Almanac

Continuous VV

The Stepwise Future of Continuous Viral Vector Manufacturing

David Alvaro, Ph.D.

Pharma's Almanac

Psychedelics CMC

The CMC Challenge for Psychedelic Drugs

David Alvaro, Ph.D.

Pharma's Almanac

ADC Linkers

Linker Chemistry as the Hidden Determinant of ADC Success

David Alvaro, Ph.D.

Pharma's Almanac

Neuro CMC

Producing Therapies for the Brain: Manufacturing and Formulation Challenges for CNS Biologics

David Alvaro, Ph.D.

Pharma's Almanac

CMC and Investment

Where Capital Meets CMC: The Emerging Role of CDMOs in Investor Risk Assessment

David Alvaro, Ph.D.; Daniel Smith, Ph.D.

Pharma's Almanac

Platforms

Built for Speed and Scale: How CDMO Cell Line Platforms Are Reshaping Biologic Development

David Alvaro, Ph.D.

Pharma's Almanac

CLD

Advancing Biologics Development With Next-Generation Cell Line Development

Woo Chi, Ph.D.; Yingji Jin, Ph.D.; Jaeeun Kim

Samsung Biologics

PPQ

Fast Path to Market: Going from GMP1 to PPQ in Just 12 Months

Jessica Feldman, Ph.D.; Henning Gerschewski

Rentschler Biopharma SE

CDMO

Revolutionary CDMO Wheeler Bio Appoints Patrick Lucy as CEO

David Alvaro, Ph.D.

Pharma's Almanac

Developability

Mitigating Early Development Risks with Samsung Biologics DEVELOPICK™ Platform

Heonchang Lim

Samsung Biologics

Digitalization

Radical Bioprocessing Efficiencies and Cost Reductions — The Next Wave of Biopharmaceutical Innovation

Michael Sokolov, Ph.D.

DataHow

IND Enablement

IND Enablement and Drug Product Development – Mitigating Risk and Accelerating through the "Valley of Death"

Johannes Clemens

Coriolis Pharma

CDMO Model

Rethinking the Conventional CDMO Model

Wheeler Bio

AAV

Overcoming Variability and Scaling Challenges in AAV Manufacturing

Rafal Garus

Viralgen Vector Core

Leap-In Transposase

Leveraging Innovative Transposase Technology for a Highly Reliable and Productive CMC Platform

Wheeler Bio

The PHASE Platform

How Synergistic Collaborations Between Outsourcing Partners Can Accelerate Clinical Success

Wheeler Bio

Advanceability

Right from the Start: Designing Advanceable Formulations and Processes at Phase I

Serán Bioscience

CMC

Revolutionizing Early-Stage Biopharma Development: Introducing Wheeler Bio's Portable CMC® Platform

Wheeler Bio